Antengene Corporation Limited
德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

INSIDE INFORMATION

COLLABORATION AGREEMENT BETWEEN ANTENGENE AND HANSOH PHARMA FOR THE COMMERCIALIZATION OF XPOVIO® (SELINEXOR) IN THE MAINLAND OF CHINA

This announcement is made by Antengene Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**" or "**Antengene**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the inside information provision (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that Antengene Corporation (Hong Kong) Limited and Antengene (Zhejiang) Pharmaceutical Technology Company Limited (德琪(浙江)醫藥科技有限公司), both subsidiaries of Antengene, have entered into an exclusive collaboration agreement (the "**Agreement**"), with Jiangsu Hansoh Pharmaceutical Group Company Limited (江蘇豪森藥業集團有限公司), a wholly-owned subsidiary of Hansoh Pharmaceutical Group Company Limited ("**Hansoh Pharma**") for the commercialization of XPOVIO® (selinexor) in the mainland of China.

XPOVIO® (selinexor) in combination with dexamethasone has been approved in the mainland of China for the treatment of relapsed/refractory multiple myeloma on December 14, 2021, and officially commercially launched in May 2022. This Agreement aims to broaden the coverage of and improve access to XPOVIO® (selinexor) for patients in the mainland of China through Hansoh Pharma's existing commercial infrastructure.

According to the terms of the Agreement, Antengene will continue to be responsible for research and development, regulatory approvals and affairs, product supply, and distribution of XPOVIO® (selinexor), while Hansoh Pharma will be exclusively responsible for commercialization of XPOVIO® (selinexor) in the mainland of China. Antengene will receive up to RMB200 million of upfront payments from Hansoh Pharma, RMB100 million of which shall be received upon signing the Agreement, and pursuant to the Agreement and subject to the terms and conditions thereof, Antengene shall be eligible to receive up to RMB100 million of the remaining upfront payments, and up to RMB535 million of milestone payments from Hansoh Pharma. Antengene will continue to record revenues of XPOVIO® (selinexor) in the mainland of China and Hansoh Pharma will receive a service fee from Antengene.

Hansoh Pharma, a company listed on the main board of The Stock Exchange of Hong Kong Limited with stock code: 3692, is an innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases, and autoimmune diseases.

To the best knowledge and belief of the Directors, as of the date of this announcement, Hansoh Pharma is independent of, and not connected with, the Company and its connected persons (as defined in the Listing Rules). The transactions contemplated under the Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

By the order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, August 11, 2023

As at the date of this announcement, the Board comprises Dr. Jay Mei, Mr. John F. Chin and Mr. Donald A. Lung as executive Directors; Dr. Kan Chen as a non-executive Director; and Ms. Jing Qian, Mr. Sheng Tang and Dr. Rafael Fonseca as independent non-executive Directors.

About XPOVIO® (selinexor)

XPOVIO® is the world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1. It offers a novel mechanism of action, synergistic effects in combination regimens, fast onset of action, and durable responses.

By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear accumulation of tumor suppressor proteins; 2) reducing the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; 3) restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway. To utilize its unique mechanism of actions, XPOVIO® is being evaluated for use in multiple combination regimens in a range of indications. At present, the Company is conducting 7 clinical studies of XPOVIO® in the mainland of China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (3 of these studies are being jointly conducted by the Company and Karyopharm Therapeutics Inc. Nasdaq: KPTI).

XPOVIO® is approved in the mainland of China for the following indication:

- In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (rrMM) who have received prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory agent, and an anti-CD38 monoclonal antibody.

About the Company

Antengene Corporation Limited ("**Antengene**", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders".

Since 2017, the Company has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, the Company has obtained 29 investigational new drug (IND) approvals in the U.S. and APAC, and submitted 10 new drug applications (NDAs) in multiple APAC markets, with the NDA for XPOVIO® (selinexor) already approved in the mainland of China, Taiwan China, Hong Kong China, South Korea, Singapore and Australia.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2022, and the documents subsequently submitted to The Stock Exchange of Hong Kong Limited.